PEPTIDEATLAS / LIBRARY
What is zenagamtide (amycretin)? Clinical status
Zenagamtide (amycretin): GLP-1/amylin mechanism, clinical development and why it is not an approved medicine.
Mechanism and research context
A unimolecular GLP-1 and amylin receptor agonist. Novo Nordisk describes zenagamtide (amycretin) as an investigational molecule in clinical development, including Phase 3 programmes; it is not an approved medicine.
Continue reading
How to assess the evidence
Check the trial, participant population, duration and comparison. Consider adverse events and discontinuations alongside the measured effect.
Results for a combination do not automatically apply to either component alone. Separate trials are not a head-to-head comparison.
What the results do not establish
Clinical findings do not establish the composition or quality of an online shop product. This profile provides no individual treatment, dosing or use instructions.
Primary source checked: 2026-09-22. Not presented as independently medically reviewed.